Snake Bites Sept 2014
|
|
- Frederick Lester
- 6 years ago
- Views:
Transcription
1 Bites Sept 2014 Epidemiology snake bites/ye, 1-4 deaths/yr in Australia. 5-10% envenomation rate Most deaths due to haematological problems Clinical envenoming Local effects (pain, swelling, bruising) Systemic symptoms Major toxin syndromes Venom-induced consumption coagulopathy (VICC) Neurotoxicity Myotoxicity Clinical examination Bite site: fang marks, bruising, local necrosis, draining lymph nodes Neurological: cranial nerves (ptosis, ophthalmoplegia, bulbar weakness), limb weakness, resp muscle weakness Haematological: evidence of abnormal coagulation (bleeding from bite site, cannula site, oral cavity, occult sites GI/GU/intracranial) Increased risk of severity 1. LOC 2. Multiple bites 3. Alcohol 4. Fast onset of symptoms 5. Brown worse than Tiger Investigations Coagulation studies INR and aptt Fibrinogen and D-dimer differentiate between VICC and anticoagulant effect D-dimer x increase Point of care INR devices give false negatives FBC and film Thrombocytopenia and red cell fragmentation = thrombotic microangiopathy Platelets fall within 24 hrs Non-specific leucocytosis and lymphopenia in systemic envenoming Biochem Serial measurements to assess renal function Elevated CK in myotoxicity but test may lag symptoms by up to 24 hrs Elevated LDH = thrombotic microangiopathy Venom Detection Kit (SVDK) Result must not be used to diagnose or exclude envenoming High rates of inaccuracy (>10% wrong identity, >25% false negatives) Assists in antivenom selection only once diagnosis of envenoming made Results must be considered with local snake geographical distributions Venom Detection Kit (SVDK) used to determine which antivenom, not if envenomed. Take swab early but don t use SVDK unless signs/symptoms of envenomation 1
2 Clinical syndromes in snake bite Sudden collapse Collapse or syncope occurring within an hour of the bite Collapse is associated with hypotension and loss of consciousness Spontaneous recovery usually occurs within minutes Minority of patients (about 5%) have a cardiac arrest or seizure Venom-induced consumption coagulopathy (VICC) Activation of the clotting pathway by prothrombin activator toxins and consumption of clotting factors (fibrinogen, factor V and factor VIII) lead to a consumptive coagulopathy Procoagulant (like DIC) Rapid onset 15-60mins, recovery 12-18hrs INR is high or unrecordable and aptt is prolonged Fibrinogen level is low or undetectable and D-dimer level is very high Complete or severe VICC is defined as: Undetectable fibrinogen, INR > 3.0 (most often unrecordable), abnormal aptt, very high D-dimer Partial VICC (less severe changes) is defined as: Low but detectable fibrinogen level (< 1.5 g/l) and INR < 3.0 Neurotoxicity A descending flaccid paralysis that classically first involves the eye muscles (ptosis, diplopia and blurred vision), followed by bulbar muscles, respiratory muscle/limb paralysis Myotoxicity Local or generalised myalgia and/or muscle tenderness CK level is usually normal (within the laboratory s reference interval) on admission and rapidly rises over hours (1000 U/L in mild cases to > U/L in severe cases) Potassium level may be elevated (> 5.0 mmol/l), renal impairment may develop Anticoagulant coagulopathy Provides a good marker of envenoming by all black snakes, including mulga snakes aptt is moderately abnormal ( laboratory s reference interval), with or without mild elevation of INR (> 1.3) D-dimer and fibrinogen levels are generally normal (D-dimer < 1.0 mg/l and fibrinogen > 1.5 g/l [or > 2.0 g/l in some laboratories]) Thrombotic microangiopathy Presence of fragmented red blood cells on blood film (microangiopathic haemolytic anaemia), thrombocytopenia and a rising creatinine level (> 120 mmol/l), which may lead to acute renal failure requiring dialysis Systemic symptoms Non-specific systemic symptoms: N/V, abdominal pain, diarrhoea, diaphoresis and headache First Aid Pressure bandage with immobilisation (PBI) wide elastic bandage Mark site of bite allows window to be cut Management A: keep patent B: 02, be aware weakness affecting resp muscles, may req BVM C: Monitor/shock/IV/fluid (generous iv hydration to prevent ARF in rhabdo) D: PRESSURE IMMOBILISATION, GCS<8?ETT Don t remove bandage ADT 2
3 Diagnostic Process - Need hospital with staff able to assess and treat anaphylaxis, lab for INR 24hrs, AV stocks 1. Establish clinical/lab evidence of envenoming (bloods and neurological exam) 2. Determine most likely snake 3. Cut hole in PIB and swab 4. If any concerns re envenoming give most appropriate antivenom 5. If well and labs normal, remove PIB in critical care area 6. If deteriorates, replace PIB 7. If no symptoms 1 hour after PIB removal admit for observation 8. Repeat bloods and neuro exam at 1hr/6hr/12hr post bite 9. If at any time any suggestion of envenomation give antivenom 10. Observe all patients for at least 12 hours Antivenom have full resus facilities available safe in children, pregnancy and lactation usually given IM; if given IV, dilute in 500ml N saline and give over 20-30mins (can stop if allergy) when discharge, give advice Re: serum sickness Polyvalent contains brown, black, tiger, taipan and death adder Absolute and Relative Indications for Antivenom Absolute indications Reported sudden collapse, seizure or cardiac arrest Abnormal INR Any evidence of paralysis, with ptosis and/or ophthalmoplegia being the earliest signs Relative indications Systemic symptoms (vomiting, headache, abdominal pain, diarrhoea) Leukocytosis Abnormal aptt CK > 1000 U/L Risks of antivenom Anaphylaxis Serum sickness Therefore give in critical area, prepare to treat for anaphylaxis (2 lines) Premedication with steroids etc not recommended Hypersensitivity reactions in 20-25% patients, more common with larger-volume antivenoms Severe anaphylaxis in 3-5% patients Serum sickness in ~1/3 patients: flu-like symptoms 4-14 days post administration Treat with prednisone 25mg OD for 5-7/7 Determining appropriate antivenom Local knowledge of snakes in area experts/snake handlers Observation of specific clinical syndromes Most parts south/central-eastern Australia one vial of each of brown and tiger snakes Smaller volume and cheaper than polyvalent antivenom, lower risk anaphylaxis Black snake, death adder and taipan rare use polyvalent antivenom One vial for both children and adults, no evidence to support further doses Black, Death Adder, Polyvalent AV - 1 ampule Brown, Taipan, Tiger AV - 2 ampules 3
4 Management of immediate reactions to antivenom 1. Stop antivenom infusion. Many reactions will resolve, and infusion then restarted at slower rate. 2. Lie patient flat, commence high-flow oxygen, support airway and ventilation if required. 3. For hypotension, give rapid infusion of 1 L normal saline (20 ml/kg in children). 4. For hypotension, hypoxaemia, wheeze or upper airway obstruction, give intramuscular adrenaline 5. Consider a cautious intravenous infusion of adrenaline avoid blood pressure surges. Patients with envenoming may be severely coagulopathic, and high blood pressure may cause or worsen intracerebral haemorrhage. Some patients can have exaggerated, hypertensive responses to intramuscular bolus adrenaline, especially to second doses. Use 1 mg in 100 ml by infusion pump: start at 0.5 ml/kg/h and titrate according to response; monitor blood pressure every 3 5 min (using the arm opposite to the infusion). Be aware that as the reaction resolves, adrenaline requirements will fall, BP will rise and the infusion rate will need to be rapidly reduced. 6. For bronchospasm, consider nebulised salbutamol. 7. For upper airway obstruction, consider nebulised adrenaline. 8. Seek further advice from a National Poisons Information Centre consultant. Other management Role of clotting factor replacement in VICC contentious FFP still given after antivenom in active bleeding/life threatening envenoming Risk of rhabdomyolysis and late neuromuscular paralysis Local Coagulopathy Neurotoxicity Myotoxicity Nephrotoxicity Life threat Sx Brown No Early (pro-c, low plt) ++ Rare No Yes Hypotension, VICC Tiger Mild Early (pro-c, low plt) Late (pre-s) Late Yes Hypotension, VICC, late paralysis + Mulga Marked Mild (anti-c) Mild Yes + Yes None Taipan Mild Early (pro-c) + Early (pre-s) + Early (mild) Yes Hypotension, VICC, paralysis (early), seizures Death Maybe No Early (post-s) + Sea No No Early Yes Yes No No Desc flaccid paralysis, hypotension 4
5 Distribution Local Symptoms Systemic Symptoms Treatment Brown Early coag Nephro LIFE THREAT Tiger Early coag Late neuro Late myo Late renal LIFE THREAT Mainland Australia Inurban areas Most common cause of severe envenoming and fatality (causes 60% snake deaths; 70% bites) Many bites don t result in systemic envenomation SE Australia Wet areas 2 nd most common cause of snake bite death (25% snake deaths) Most bites result in systemic envenomation Trivial local features Ooze at bite site Mild local redness, swelling +/- bruising over 3hrs Pain in 50% Rapid onset symptoms early collapse; maybe death <1hr due to cardiotoxicity Non-specific (N+V+H+AP), tender regional lymphadenopathy Early severe coagulopathy (pro-c, decr plt, decr FDP, VICC) may occur despite minimal Sx; risk of major haemorrhage) Thrombotic microangiopathy (10%) decr plt ARF (lasting 2-8/52) haemolytic anaemia Maybe renal failure (direct nephrotoxic effect) Rhabdo and neurotox rare May be early collapse / death due to cardiotoxicity Non-specific (as above), tender regional lymphadenopathy Early coagulopathy (pro-c, decr plt, VICC) Gradual onset neurotoxicity (pres) (over 1-2hrs) Late severe myotoxicity and renal failure (over hrs) Brown AV Hypotension VICC -uncontrolled haemorrhage FFP if actively bleeding Tiger AV VICC with uncontrolled haemorrhage, paralysis with resp failure, hypotension Black (Mulga) Black Taipan N Australia Dry areas Marked local pain redness, swelling +/- bruising over 3hrs Tender regional LN s (60%) Investigation: incr INR, decr fib, incr D-dimer, incr FDP Non-specific - headache, nausea, abdo pain, vomiting Myotoxicity (onset in 6hrs, lasts days, incr CK) and renal failure Coagulopathy (mild; anti-c, incr APTT and INR) usually not clinically significant Neurotoxicity (mild, occurs in 15%) If refractory GI Sx or rhabdo (CK >5000) PIB - Yes Black AV SE Australian coast Local pain Rare; minor myolysis only Rarely requires AV Tiger AV N and E Australia Dry areas 10% deaths Mild local redness, swelling +/- bruising over 3hrs Rapid severe systemic symptoms: most deadly snake in the world Non-specific Collapse Early Coagulopathy (pro-c, VICC) Early neurotoxicity (paralysis 1-2hrs, seizures) Early mild myotoxicity Life threatening Taipan AV Hypotension Paralysis VICC Seizures Death Adder All Australia Nocturnal 5% deaths Mod-severe local pain; little local signs Early neurotoxicity progressive symmetrical descending flaccid paralysis within 6hrs resp arrest Risk of delayed symptoms Life threatening Death Adder AV 24hrs 5
Princess Alexandra Hospital Emergency Department. Clinical Module. Clinical features of envenoming: Major toxin syndromes 1 :
Princess Alexandra Hospital Emergency Department Clinical Module Toxicology Review Officer: Toxicology registrar Version no: 1 Approval date: February 2017 Review date: February 2019 Approving Officer
More informationSnake bite: a current approach to management
Snake bite: a current approach to management Geoffrey K Isbister, Senior Research Fellow, Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Northern Territory, Clinical
More informationClinical focus. Snakebite in Australia: a practical approach to diagnosis and treatment. Clinical focus. Summary. Clinical effects.
Clinical focus Geoffrey K Isbister BSc, FACEM, MD, Associate Professor, 1 and Clinical Toxicologist 2 Simon G A Brown MB BS, PhD, FACEM, Emergency Physician and Professor 3 Colin B Page MB ChB, FACEM,
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Johnston CI, Ryan NM, Page CB, et al. The Australian Snakebite
More informationPOLYVALENT SNAKE ANTIVENOM Product Information 1(5) Product Information POLYVALENT SNAKE ANTIVENOM (AUSTRALIA - PAPUA NEW GUINEA) AUST R 74899
POLYVALENT SNAKE ANTIVENOM Product Information 1(5) Product Information NAME OF THE MEDICINE POLYVALENT SNAKE ANTIVENOM (AUSTRALIA - PAPUA NEW GUINEA) AUST R 74899 DESCRIPTION POLYVALENT SNAKE ANTIVENOM
More informationProduct Information BROWN SNAKE ANTIVENOM AUST R 74897
Product Information APPROVED NAME BROWN SNAKE ANTIVENOM AUST R 74897 DESCRIPTION BROWN SNAKE ANTIVENOM is prepared from the plasma of horses immunised with the venom of the brown snake (Pseudonaja textilis).
More informationSpecific treatment: Antivenom (AV) Therapy
Specific treatment: Antivenom (AV) Therapy It is never too late to give antivenom provided the indications are present: Only if features of systemic envenoming are present for bites of snakes in the red
More informationANTIVIPMYN TREATMENT PACKAGE
The Ontario Massasauga Rattlesnake Antivenom Depot Dr. T. J. Fargher, MB. Ch.B., F.C.P (SA), F.R.C.P(C) Medical Director 705-746-9321 ANTIVIPMYN TREATMENT PACKAGE FOR EASTERN MASSASAUGA RATTLESNAKE BITES
More informationChanges in serial laboratory test results in snakebite patients: when can we safely exclude envenoming?
Changes in serial laboratory test results in snakebite patients: when can we safely exclude envenoming? Graham Ireland, Simon G A Brown, Nicholas A Buckley, Jeff Stormer, Bart J Currie, Julian White, David
More informationSTATE TOXINOLOGY SERVICES Toxinology Dept., Women s & Children s Hospital, North Adelaide SA 5006 AUSTRALIA
Family Elapidae www.toxinology.com record number SN0170 Scientific name combined Common name Black Mamba, Black-mouthed Mamba Global region in which snake is found CLINICAL OVERVIEW Mambas are amongst
More informationSTATE TOXINOLOGY SERVICES Toxinology Dept., Women s & Children s Hospital, North Adelaide SA 5006 AUSTRALIA
Family Viperidae www.toxinology.com record number Common name Eyelash Palm Pit Viper SN0379 Scientific name combined Global region in which snake is found Central America + South America CLINICAL OVERVIEW
More informationSNAKEBITE / CROTALID ANTIVENOMS
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationSTATE TOXINOLOGY SERVICES Toxinology Dept., Women s & Children s Hospital, North Adelaide SA 5006 AUSTRALIA
Family Viperidae www.toxinology.com record number Common name Western Diamond Rattlesnake SN0419 Scientific name combined Global region in which snake is found North America + Central America CLINICAL
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationHaematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital
Haematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital Case Number 1 43 year old male presenting with fevers, abdominal distension and weight gain over 2 weeks.
More informationCollett s snake (Pseudechis colletti ) envenoming in snake handlers
Q J Med 2006; 99:109 115 Advance Access publication 24 January 2006 doi:10.1093/qjmed/hcl007 Collett s snake (Pseudechis colletti ) envenoming in snake handlers G.K. ISBISTER 1,2, M.R. HOOPER 3, R. DOWSETT
More informationPLASMA EXCHANGE J MANION NEPEAN HOSPITAL
PLASMA EXCHANGE J MANION NEPEAN HOSPITAL PLASMA The fluid portion of blood Normally approx 5% body weight or 3.5L in 70kg male Clots on standing unless anticoagulated Common plasma proteins are albumin,
More informationBEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL
Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*
More informationEffect of under filling tube
Effect of under filling tube 2 What constitutes underfilling? A 4.5ml vacutainer collection tube should contain at least 4ml of blood Less than that could give falsely prolonged clotting times ALSO be
More informationNursing Management Pre /Post Thrombolysis in Stroke
Craigavon Area Hospital Guidelines for Nursing Management Pre /Post Thrombolysis in Stroke 1. A senior nurse in the stroke unit will be required to monitor the patients condition post Thrombolysis on a
More informationKeeping track of your numbers
Keeping track of your numbers If you have relapsed or refractory multiple myeloma, keeping track of your numbers can help you take an active role in your care. It s also one way you and your doctor can
More informationCandidate number BOOK TWO. NSW Fellowship Course - SAQ trial paper
BOOK TWO QUESTION 10 (20 marks) DOUBLE QUESTION You are the consultant in a regional Emergency Department. A 5 year old girl re-presents having been discharged 7 hours ago. She was assessed during the
More informationOxaliplatin and Gemcitabine
Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen
More informationSTATE TOXINOLOGY SERVICES Toxinology Dept., Women s & Children s Hospital, North Adelaide SA 5006 AUSTRALIA
Family Viperidae www.toxinology.com record number SN0200 Scientific name combined Common name Puff Adder, Common Puff Adder, African Puff Adder ( B. a. arietans ), Somali Puff Adder ( B. a. somalica )
More informationThrombolysis for acute ischaemic stroke Rapid Assessment Protocol NORTHERN IRELAND Regional Protocol (Version 002 July 08)
Thrombolysis for acute ischaemic stroke Rapid Assessment Protocol NORTHERN IRELAND Regional Protocol (Version 002 July 08) Patient Details Time of onset? Capillary Blood glucose 2.8-22.2 mmol/l? Blood
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS I. Purpose : A. To reduce morbidity and mortality associated
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationGemcitabine, Carboplatin and Bevacizumab (gynae)
Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationTransfusion Challenges. - Transfusion Reactions - Do they need platelets? Dr. Eoghan Molloy Haem SpR 2016
Transfusion Challenges - Transfusion Reactions - Do they need platelets? Dr. Eoghan Molloy Haem SpR 2016 Guidance on Transfusion Hospital transfusion guidelines and procedures Irish Blood Transfusion Service
More informationManagement of an immediate adverse event following immunisation
Management of an immediate adverse event following immunisation The vaccinated person should remain under observation for a short interval to ensure that they do not experience an immediate adverse event.
More informationBMS Education Day 28 th January and 4th February 2013
BMS Education Day 28 th January and 4th February 2013 Category of Reaction 24 hours from the transfusion = DELAYED Infectious Bacterial contamination Viral HIV,
More informationThings to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC
Things to never miss in the office Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC Presenter Disclosure Faculty / Speaker s name: Brett Houston / Leonard Minuk Relationships with commercial
More informationCBC with Differential. PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT Non Categorized SUB ED Snakebite Protocol (SUB)* Non Categorized ***(NOTE)*** This plan is designed to be used as part of a larger plan, not independently. Please do NOT order individually.
More informationAustralian Spider Bites. Dr Sanj Fernando
Australian Spider Bites Dr Sanj Fernando Funnel Web Spider Atrax robustus Funnel-Web Spider details Large spider - usually seen fangs (4mm long) can penetrate a nail aggressive - bites repeatedly venom
More informationThrombolysis administration
Thrombolysis administration Liz Mackey Stroke Nurse Practitioner Western Health Sunshine & Footscray Hospital, Melbourne Thanks ASNEN committee members Skye Coote, Acute Stroke Nurse, Eastern Health (slide
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationUHSM ED Pathway ELDERLY FALL / COLLAPSE
UHSM ED Pathway ELDERLY FALL / COLLAPSE Patient name / Pathway for patients who require assessment in ED after a fall or collapse Note: - It can be used if the patient has also sustained a minor head injury
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationThrombolysis Delivery, Care, and Monitoring. 5 Acute Trusts - 6 Primary Care Trusts Ambulance Trust 4 Local Authorities
Thrombolysis Delivery, Care, and Monitoring Documentation & Pathways Need to follow locally agreed policies and procedures Follow thrombolysis pathway? Need to complete Sits database Weight Dose matters!
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationEnvironmental Summary Dec 2014
Environmental Summary Dec 2014 Diving Medicine Problems of descent 1. Mask and external ear squeeze 2. Middle ear squeeze - TM ruptures 3. Inner ear barotrauma 4. Dental squeeze 5. Nitrogen narcosis 6.
More informationCASE REPORT RENAL FAILURE AND DIC-LIKE SYNDROME FOLLOWING SNAKE BITES
CASE REPORT RENAL FAILURE AND DIC-LIKE SYNDROME FOLLOWING SNAKE BITES Fransciscus Ginting, Restuti, Endang, Tambar Kembaren, Yosia Ginting, Ricky Rivalino Sitepu Tropical Infenction Medicine - Internal
More informationSTORMY DENGUE with bloody problems. Anand M.Patil PICU MED/SURG TEAM Apollo Childrens Hospitals Chennai
STORMY DENGUE with bloody problems Anand M.Patil PICU MED/SURG TEAM Apollo Childrens Hospitals Chennai 1 HISTORY 4 ½ years girl Day 1: Fever, Lethargy, Low urine output Hypotension, high PCV,low platelets
More informationPalliative Care Emergencies
Palliative Care Emergencies LAURA BARNFIELD What might constitute an emergency in Palliative Care? 1 Palliative Care Emergencies Major haemorrhage Metastatic Spinal Cord Compression (MSCC) Superior Vena
More informationACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
More informationTACO CASE STUDIES RTC JUNE Kerry Dowling Blood Transfusion Laboratory Manager Jonathan Ricks Blood Transfusion Nurse Practitioner
TACO CASE STUDIES RTC JUNE 2017 Kerry Dowling Blood Transfusion Laboratory Manager Jonathan Ricks Blood Transfusion Nurse Practitioner RISK FACTORS - TACO Age over 70 years although also seen in younger
More informationSTATE TOXINOLOGY SERVICES Toxinology Dept., Women s & Children s Hospital, North Adelaide SA 5006 AUSTRALIA
Family Elapidae www.toxinology.com record number SN0184 Scientific name combined Common name Mocambique Spitting Cobra, m Fezi, Mozambique Spitting Cobra Global region in which snake is found Sub-Saharan
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationProtocol for IV rtpa Treatment of Acute Ischemic Stroke
Protocol for IV rtpa Treatment of Acute Ischemic Stroke Acute stroke management is progressing very rapidly. Our team offers several options for acute stroke therapy, including endovascular therapy and
More informationGUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS
GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol
More informationAllergic Emergencies and Anaphylaxis. George Porfiris MD, CCFP(EM),FCFP TEGH
Allergic Emergencies and Anaphylaxis George Porfiris MD, CCFP(EM),FCFP TEGH Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationSnake Envenomation CLINICAL SIGNS DIAGNOSTICS PATHOPHYSIOLOGY
Snake Envenomation CLINICAL SIGNS Pre-paralytic signs - Collapse with recovery vs lethal - Tachypnea - Vomiting/Defecation - Ptyalism - Muscle tremors Paralytic signs loss of corneal and/or pupillary light
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationAGWS Stroke Thrombolysis Clinical Profoma
AGWS Stroke Thrombolysis Clinical Profoma Incorporating Salisbury NHS Foundation Trust guidance Date: On Arrival: Affix patient label here) GCS NIHSS Score: Pulse SaO on Air Give O only if < 95 % on Air
More informationDR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL
DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL Rare but fatal disease if unrecognized and untreated Incidence about 1: 1 million in the USA Female preponderance of 2:1 Part
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages
More informationFuel your determination to live longer with KYPROLIS. Look inside to learn more.
F O R R E L A P S E D MULT IP L E M Y E L OM A APPROVED USES KYPROLIS is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous
More informationSalicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.
Aspirin poisoning CLINICAL FEATURES Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Severe poisoning causes
More information11/27/2017. Stroke Management in the Neurocritical Care Unit. Conflict of interest. Karel Fuentes MD Medical Director of Neurocritical Care
Stroke Management in the Neurocritical Care Unit Karel Fuentes MD Medical Director of Neurocritical Care Conflict of interest None Introduction Reperfusion therapy remains the mainstay in the treatment
More informationCARDIAC ARREST IN SPECIAL CIRCUMSTANCES 2
CARDIAC ARREST IN SPECIAL CIRCUMSTANCES 2 M1 Objectives To understand how resuscitation techniques should be modified in the special circumstances of: Hypothermia Immersion and submersion Poisoning Pregnancy
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationApproach to disseminated intravascular coagulation
Approach to disseminated intravascular coagulation Khaire Ananta Shankarrao 1, Anil Burley 2, Deshmukh 3 1.MD Scholar, [kayachikitsa] 2.Professor,MD kayachikitsa. 3.Professor and HOD,Kayachikitsa. CSMSS
More informationPolicy for the use of intravenous Iron Dextran (CosmoFer )
Policy for the use of intravenous Iron Dextran (CosmoFer ) Sharepoint Location Clinical Policies and Guidelines Sharepoint Index Directory General Policies and Guidelines Sub Area Haematology and Blood
More informationHave you ever managed patients who have experienced an adverse reaction to transfusion?
Have you ever managed patients who have experienced an adverse reaction to transfusion? A. Yes, often B. Yes, occasionally C. No A. 1 in 30 units? B. 1 in 100? C. 1 in 1000? D. 1 in 10,000? SHOT collects
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Clostridium botulinum neurotoxin type A haemagglutinin complex Pharmaceutical form(s)/strength: powder for solution for injection, 300 unit and 500 unit P-RMS:
More informationDRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)
Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus
More informationNab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate 1 8 15 Sodium Chloride 0.9% 100ml Infusion Fast Running Dexamethasone 8mg Oral Ondansetron 8mg Oral/ IV Chlorphenamine 10mg Intravenous Slow
More informationWhat is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
More informationMajor Haemorrhage Protocol. Commentary
Hairmyres Hospital Monklands Hospital Wishaw General Hospital Major Haemorrhage Protocol Commentary N.B. There is a separate NHSL protocol for the Management of Obstetric Haemorrhage Authors Dr Tracey
More informationLOSS OF CONSCIOUSNESS & ASSESSMENT. Sheba Medical Center Acute Medicine Department MATTHEW WRIGHT
LOSS OF CONSCIOUSNESS & ASSESSMENT Sheba Medical Center Acute Medicine Department MATTHEW WRIGHT OUTLINE Causes Head Injury Clinical Features Complications Rapid Assessment Glasgow Coma Scale Classification
More informationAnaphylaxis/Latex Allergy
Children s Acute Transport Service CATS Clinical Guideline Anaphylaxis/Latex Allergy Document Control Information Author D Lutman Author Position Consultant Document Owner E Polke Document Owner Position
More informationHerceptin IV (Trastuzumab) and Paclitaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Given as a three weekly schedule Day Drug Daily Dose Route Diluent & Rate On first cycle 250mls Normal Saline Herceptin IV 8 mg/kg Infusion only 90 mins On other 250mls Normal
More informationMANAGEMENT OF DENGUE INFECTION IN ADULTS (Revised 2 nd Edition) QUICK REFERENCE FOR HEALTHCARE PROVIDERS
1 KEY MESSAGES Dengue is a dynamic disease and presented in three phases - febrile phase, critical phase and recovery phase. Clinical deterioration often occurs in the critical phase and is marked by plasma
More informationAdverse drug reactions. Dr. Mark Haworth MBChB DA MRCA
Adverse drug reactions Dr. Mark Haworth MBChB DA MRCA Types of drug reaction The appearance of known side effects to a drug e.g. respiratory depression following the administration of opioid analgesics
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationCAUTION: You must refer to the intranet for the most recent version of this procedural document.
Procedure for the use of Intravenous Iron Dextran (CosmoFer ) Sharepoint Location Sharepoint Index Directory Clinical Policies and Guidelines General Policies and Guidelines/ Haematology And blood transfusion
More informationStudy of clinical profile complications and outcome in patients of snake bite in pediatric age group
Original article: Study of clinical profile complications and outcome in patients of snake bite in pediatric age group A.M. Lingayat, P.R. Wankhade Department of Pediatrics, Government Medical College,
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationStroke Transfer Checklist
Stroke Transfer Checklist When preparing to transfer an acute stroke patient to the UF Health Shands Comprehensive Stroke Center, please make every attempt to include the following information: Results
More informationSTATE TOXINOLOGY SERVICES Toxinology Dept., Women s & Children s Hospital, North Adelaide SA 5006 AUSTRALIA
Family Elapidae www.toxinology.com record number SN0045 Scientific name combined Common name Thai Spitting Cobra, Isan Spitting Cobra Global region in which snake is found Southeast Asia CLINICAL OVERVIEW
More informationE 90 C followed by Weekly Paclitaxel
E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29
Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationDBL MAGNESIUM SULFATE CONCENTRATED INJECTION
DBL MAGNESIUM SULFATE CONCENTRATED INJECTION NAME OF MEDICINE Magnesium Sulfate BP DESCRIPTION DBL Magnesium Sulfate Concentrated Injection is a clear, colourless, sterile solution. Each ampoule contains
More informationGUIDELINE FOR HAEMODIALYSIS PRESCRIPTION FOR NEW PATIENTS COMMENCING HAEMODIALYSIS
GUIDELINE FOR HAEMODIALYSIS PRESCRIPTION FOR NEW PATIENTS COMMENCING HAEMODIALYSIS RRCV CMG Nephrology Service 1. Introduction A first acute or chronic haemodialysis session may induce disequilibrium syndrome
More informationLIVE LONGER. Chart a course that could help you. If multiple myeloma comes back:
1 If multiple myeloma comes back: Chart a course that could help you 1 LIVE LONGER -3 In two clinical studies with patients with relapsed multiple myeloma, two KYPROLIS -based combinations kept multiple
More informationCARFILZOMIB /DEXAMETHASONE (CarDex)
CARFILZOMIB /DEXAMETHASONE (CarDex) INDICATIONS First Relapse multiple myeloma in bortezomib naïve patients [NICE TA457] Requires Blueteq Application TREATMENT INTENT Disease modification PRE-ASSESSMENT
More informationThese guidelines have been developed by: Dr Peter Pereira, MBBS (UNSW), FACEM Director, Emergency Medicine, Cairns Base Hospital, Queensland.
Please refer to the following pages for the emergency management of the Irukandji Syndrome that has been developed through the Prevention and Response Working Group of the Irukandji Taskforce. These guidelines
More informationNEONATAL HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE) & COOLING THERAPY
Background NEONATAL HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE) & COOLING THERAPY A perinatal hypoxic-ischaemic insult may present with varying degrees of neonatal encephalopathy, neurological disorder and
More informationBreast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Indication: First-line or second-line treatment of triple negative advanced breast cancer National Cancer Drug Fund criteria: Advanced
More informationSign up to receive ATOTW weekly -
ANAPHYLAXIS ANAESTHESIA TUTORIAL OF THE WEEK 38 1 th DECEMBER 2006 Dr. Sara Rees Cardiff, UK Case History You are anaesthetising a fit and well 40 year old woman for total abdominal hysterectomy for menorrhagia.
More informationAdministration of blood components. Tina Parker - Transfusion Practitioner
. Administration of blood components Tina Parker - Transfusion Practitioner Red Cells Each unit contains 250-350mls Preserved with glucose and Mannitol to keep the correct tension Lasts 35 days from midnight
More informationFOLFIRINOX (Irinotecan, Oxaliplatin & infusional Fluorouracil) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate Glucose 5% 250ml Infusion Fast Running for Line Flush Day 1 Ondansetron 8mg IV bolus Via dextrose drip Dexamethasone 8mg IV bolus Via dextrose
More information